Health regulators in Ireland, Belgium, and the Netherlands have approved Libmeldy, a groundbreaking gene therapy, making it the most expensive drug to receive official endorsement in European countries. The respective national Health services have approved Atidarsagene autotemcel – also known under the brand name Libmeldy – a gene therapy developed by Orchard Therapeutics, the Irish Minister for Health Stephen Donnelly announced. The treatment – which costs around €2.5 million per dose – targets the most severe cases of a rare genetic disorder, metachromatic leukodystrophy (MLD) that causes da…
